ALNY vs. NVS: Alnylam Pharmaceuticals vs. Novartis Stock Comparison

Company Profile

Alnylam Pharmaceuticals (ALNY) and Novartis (NVS) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but ALNY is classified in Biotechnology while NVS is classified in Pharmaceuticals.

Alnylam Pharmaceuticals (ALNY) trades as ordinary local shares, while Novartis (NVS) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Both companies show strong equity returns, but Alnylam Pharmaceuticals (ALNY) at 138.07% is the standout with ROE above its industry range; Novartis (NVS) at 24.33% also sits in the top quartile.

Alnylam Pharmaceuticals (ALNY) at 52.85% keeps the most of each sales dollar — above its industry’s net margin range — and Novartis (NVS) at 17.49% also retains a top-quartile share.

Both Alnylam Pharmaceuticals (ALNY) at 23.72% and Novartis (NVS) at 34.27% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

Profitability Metrics

Growth

Alnylam Pharmaceuticals (ALNY) at 65.19% sits in the top revenue growth quartile, while Novartis (NVS) at 9.57% is closer to the peer norm — faster top-line expansion for ALNY.

Only one side can be read here: Novartis (NVS) reports EPS growth of 21.81%, ranked against its industry; Alnylam Pharmaceuticals (ALNY) has no EPS growth figure this period.

Growth Metrics

Financial Strength

Alnylam Pharmaceuticals (ALNY) at 2.48 keeps current ratio within its industry’s typical mid-range, while Novartis (NVS) at 0.88 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for NVS.

Both Alnylam Pharmaceuticals (ALNY) at 0.83 and Novartis (NVS) at 1.29 lean more heavily on debt funding than most peers, landing in the higher-leverage quartile of their industries.

Financial Strength Metrics

Dividends

Alnylam Pharmaceuticals (ALNY) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Novartis (NVS) reports a yield of 2.88%, ranking against industry peers normally.

Alnylam Pharmaceuticals (ALNY) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Novartis (NVS) reports a payout of 90.46%, ranking against industry peers normally.

Dividend Metrics

Valuation

Alnylam Pharmaceuticals (ALNY) at 7.88 sits in the cheaper P/E ratio quartile, while Novartis (NVS) at 31.02 is closer to its industry’s usual earnings multiple — a discount for ALNY, though growth and earnings durability still matter.

On P/S ratio, both Alnylam Pharmaceuticals (ALNY) at 4.17 and Novartis (NVS) at 5.35 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

Alnylam Pharmaceuticals (ALNY) at 5.79 is valued about in line with its industry on P/B ratio, while Novartis (NVS) at 8.25 carries an above-peer premium to book — NVS is pricier on assets.

Valuation Metrics